Last checked: August 21, 2026. The state count and baseline table reflect the KFF January 2026 snapshot of fee-for-service programs, supplemented by public state information. This is not a live eligibility tool. Coverage for GLP-1s used for type 2 diabetes, cardiovascular risk or other approved indications works differently. Follow broader policy and access changes in the GLP-1 updates log. Rules and managed-care policies can change, so confirm with your own state Medicaid program. Spot a change? Tell us.
States that cover weight-loss GLP-1s
As of KFF's January 2026 snapshot, with public-source updates noted below. "Restricted" means coverage exists but with extra criteria, such as BMI thresholds or step requirements.
| State | Obesity coverage | Notes |
|---|---|---|
| Delaware | Yes | Fee-for-service |
| Minnesota | Yes | Fee-for-service |
| Mississippi | Yes | Fee-for-service |
| Missouri | Yes | Fee-for-service |
| North Carolina | Yes | Cut Oct 2025, reinstated Dec 2025 |
| Rhode Island | Yes | Fee-for-service |
| Tennessee | Yes | Fee-for-service |
| Utah | Yes | Fee-for-service |
| Virginia | Yes | Fee-for-service |
| Wisconsin | Yes | Fee-for-service |
| Kansas | Restricted | Severe-obesity / CVD pathway |
| Massachusetts | Restricted | BMI criteria; narrowing from July 1, 2026 |
| Michigan | Restricted | Morbid obesity; prior interventions required |
KFF's January 2026 fee-for-service snapshot did not identify other state programs covering GLP-1s for obesity in this category. Managed-care plans and later state policy changes can differ, so verify with your state before relying on it.
What just changed
| Change | States | When |
|---|---|---|
| Dropped obesity coverage | California, New Hampshire, Pennsylvania, South Carolina | Effective Jan 1, 2026 |
| Reinstated after a cut | North Carolina | Dec 2025 (cut in Oct 2025) |
| Narrowing criteria | Massachusetts | From July 1, 2026 |
How Medicaid GLP-1 coverage actually works
- Obesity coverage is optional. Federal rules let states choose whether Medicaid covers weight-loss drugs, so it varies state to state, and the trend in 2025–2026 has been fewer states covering, driven by cost.
- Diabetes and heart-risk coverage is different. When a GLP-1 is prescribed for type 2 diabetes or cardiovascular risk (its approved medical uses), Medicaid coverage is far more common everywhere.
- Prior authorization is the norm. Even in covering states, expect BMI thresholds, documentation and step requirements.
- The BALANCE Model may expand access. CMS describes a voluntary model that can launch in Medicaid as early as May 2026. Participation and individual coverage are not guaranteed, and states can join through January 1, 2027.
How we track this
We compile this from KFF's national analysis, the current CMS BALANCE page and public state Medicaid documents. The scope is fee-for-service obesity or weight-management coverage, not every managed-care plan or every medically accepted indication. A “yes” in this table does not mean every product, person or prescription is covered. The definitive answer for you is always your own state Medicaid program or your prescriber's office. For the bigger picture on paying for a GLP-1, see our cost and insurance guide and the price tracker.
Sources
- KFF, Medicaid Coverage of and Spending on GLP-1s.
- CMS, BALANCE Model.
- Medicaid.gov state overviews and public state Medicaid policy pages.
- State policy changes are recorded only when a public source can be checked. This page does not claim to monitor every managed-care plan in real time.
Methodology and change log
Scope: This tracker focuses on fee-for-service Medicaid coverage of GLP-1 medicines for obesity or weight management. Diabetes, cardiovascular, sleep-apnea and other approved indications are separate coverage questions. Managed-care plans, employer plans and individual eligibility can differ.
Review process: We use KFF's January 2026 national snapshot as the baseline, check the current CMS BALANCE page for model status and dates, and use public state Medicaid documents for changes. We do not infer coverage from a drug appearing on a formulary alone, and we do not turn a state-level result into an individual eligibility conclusion.
Change log: August 21, 2026, updated the page date, clarified that the table is based on KFF's January 2026 snapshot, added CMS and Medicaid.gov links, and revised the BALANCE description to reflect voluntary participation and non-guaranteed coverage. July 2026, previous tracker snapshot.
Frequently asked questions
Does Medicaid cover GLP-1s for weight loss? +
It depends on the state and program. KFF reported 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service as of January 2026. Coverage for type 2 diabetes and other approved indications is a separate question.
Which states cover weight-loss GLP-1s? +
KFF's January 2026 fee-for-service snapshot identified Delaware, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin, plus Kansas, Massachusetts and Michigan with restrictions. This is a dated state snapshot, not an individual coverage determination.
Why don't more states' Medicaid cover weight-loss GLP-1s? +
Cost is a major factor. Medicaid obesity coverage is optional for states, and several programs have narrowed or dropped coverage amid budget pressure. Roughly 80% of adult Medicaid enrollees live in states that do not cover GLP-1s for obesity through fee-for-service.
Is this a live Medicaid eligibility checker? +
No. This is a dated fee-for-service state snapshot. Managed-care plans, product rules, approved uses and individual eligibility can differ. Confirm coverage with the relevant state Medicaid program.
Does the BALANCE Model guarantee coverage? +
No. CMS describes BALANCE as voluntary for states, manufacturers and plans, and says coverage depends on participation and negotiated eligibility criteria. It does not guarantee coverage for an individual.